Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23414587 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Condition: BRAF or NRAS Mutant Metastatic Melanoma
Intervention: Drug: MEK162

Indicates status has not been verified in more than two years